(19)
(11) EP 3 606 570 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
01.01.2025 Bulletin 2025/01

(45) Mention of the grant of the patent:
27.11.2024 Bulletin 2024/48

(21) Application number: 18781472.8

(22) Date of filing: 05.04.2018
(51) International Patent Classification (IPC): 
A61L 27/22(2006.01)
A61L 27/24(2006.01)
C07K 14/47(2006.01)
A61P 27/02(2006.01)
 A61L 27/54(2006.01)
A61L 17/08(2006.01)
A61K 38/39(2006.01)
(52) Cooperative Patent Classification (CPC):
A61L 27/24; A61L 27/54; A61K 38/39; A61L 17/08; A61L 27/10; A61L 29/045; A61L 29/085; A61L 29/16; A61L 31/044; A61L 31/10; A61L 31/16; A61L 2400/12; C07K 14/78; A61K 38/014; A61P 17/00; A61K 31/497; A61K 31/351; A61P 35/00; A61P 19/02; A61P 27/02; A61P 29/00; A61L 17/005
(86) International application number:
PCT/US2018/026180
(87) International publication number:
WO 2018/187530 (11.10.2018 Gazette 2018/41)

(54)

COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS FOR USE IN THE TREATMENT OF OCULAR DISEASES, DISORDERS OR WOUNDS

ARZNEIZUSAMMENSETZUNGEN AUF DER BASIS VON KOLLAGENPEPTID ZUR VERWENDUNG IN DER BEHANDLUNG AUGENKRANKHEITEN, -STÖRUNGEN ODER -WUNDEN

COMPOSITIONS MÉDICAMENTEUSES À BASE DE COLLAGÈNE PEPTIDIQUE POUR L'UTILISATION DANS LE TRAITEMENT DES MALADIES, TROUBLES OU BLESSURES OCULAIRES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 06.04.2017 US 201762482592 P
06.11.2017 US 201762581927 P

(43) Date of publication of application:
12.02.2020 Bulletin 2020/07

(60) Divisional application:
24210252.3 / 4477267

(73) Proprietor: Sustain Holdings, LLC
Stuart, FL 34994 (US)

(72) Inventors:
  • SCHLUMPF, Richard Eric
    Stuart, FL 34997 (US)
  • BARATTA, Robert
    Stuart, FL 34997 (US)
  • DELOREY, Shawn A.
    Charles, NC 28210 (US)

(74) Representative: Latscha Schöllhorn Partner AG 
Grellingerstrasse 60
4052 Basel
4052 Basel (CH)


(56) References cited: : 
WO-A1-2016/165788
US-A1- 2015 111 308
 WO-A2-2007/044026
   
  • CHATTOPADHYAY, S ET AL.: "Anchoring a Cytoactive Factor in a Wound Bed Promotes Healing", JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE, vol. 10, no. 12, December 2016 (2016-12-01), pages 1012 - 1020, XP055544458, [retrieved on 20140327]
  • GARG, P ET AL.: "To Study the Efficacy of Difluprednate Ophthalmic Emulsion and Prednisolone Acetate Ophthalmic Suspension on Post-operative Inflammation in Cataract Surgery", JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, vol. 10, no. 12, December 2016 (2016-12-01), pages NC05 - NC08, XP055544467, [retrieved on 20161201]
  • MA, B ET AL.: "Crosslinking strategies for preparation of extracellular matrix-derived cardiovascular scaffolds", REGENERATIVE BIOMATERIALS, vol. 1, no. 1, November 2014 (2014-11-01), pages 81 - 89, XP055544473, [retrieved on 20141020]
  • KARTHIKEYAN, D ET AL.: "The concept of ocular inserts as drug delivery systems: An overview", ASIAN JOURNAL OF PHARMACEUTICS, vol. 2, no. 4, October 2008 (2008-10-01), pages 192 - 200, XP055544482
  • JOSEPH, RR ET AL.: "Drug delivery to the eye: what benefits do nanocarriers offer?", NANOMEDICINE, vol. 12, no. 6, March 2017 (2017-03-01), pages 683 - 702, XP055435107, [retrieved on 20170210]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).